Pico145 inhibits TRPC4-mediated mICAT and postprandial small intestinal motility

Dariia O Dryn1, Mariia I Melnyk2, Robin S Bon3

  • 1A.A. Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, 4 Bogomoletz Str., Kyiv 01024, Ukraine.

Insights

The TRPC4 inhibitor Pico145 potently blocks muscarinic receptor cation current (mICAT) in mouse ileal myocytes at picomolar concentrations. This compound effectively reduces intestinal motility and delays transit, demonstrating its potential as a GI-active therapeutic.

Area of Science:

  • Physiology
  • Pharmacology
  • Gastroenterology

Background:

  • TRPC4 channels are key mediators of muscarinic receptor cation current (mICAT) in intestinal smooth muscle, driving cholinergic excitation-contraction coupling.
  • Understanding the role of TRPC4 and developing targeted inhibitors is crucial for modulating gastrointestinal motility.

Purpose of the Study:

  • To investigate the effects of the novel TRPC4 inhibitor Pico145 on mICAT, intracellular calcium (Ca2+) signaling, and intestinal motility in mouse models.

Main Methods:

  • Patch-clamp electrophysiology and Fura-2 imaging were used to assess mICAT and Ca2+ dynamics in isolated ileal myocytes.
  • In vitro tensiometry, ex vivo video recordings, and in vivo carmine red transit measurements evaluated the functional impact on intestinal motility.

Main Results:

  • Pico145 demonstrated potent inhibition of carbachol-induced mICAT with an IC50 of 3.1 pM and inhibited Ca2+ rises with an IC50 of 2.7 pM.
  • The inhibitor suppressed spontaneous and evoked intestinal smooth muscle contractions and significantly delayed postprandial intestinal transit.
  • Pico145's efficacy in vivo was comparable to TRPC4 gene deficiency.

Conclusions:

  • Pico145 is a highly potent small-molecule inhibitor of TRPC4 channels, effectively suppressing mICAT at picomolar concentrations.
  • The compound exhibits significant gastrointestinal activity, reducing muscle contractions and delaying transit, highlighting its therapeutic potential for motility disorders.

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
272
Gastric Motility01:16

Gastric Motility

Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
772
Enteric Nervous System: Regulation of GI Motor Activity01:11

Enteric Nervous System: Regulation of GI Motor Activity

The Enteric Nervous System (ENS) plays a pivotal role in regulating gastrointestinal or GI motor activity. This complex network of nerves, deeply embedded within the gut wall, responds to changes in the gut environment and receives input from both the autonomic nervous system and the central nervous system. By doing so, the ENS operates various programs tailored to the body's nutritional status and needs.
During periods of fasting, the ENS initiates the migrating myoelectric complex, a...
406
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
350
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
394